PF-2545920

PF-2545920 Basic Attributes

Characteristics

Latest News on PF-2545920

• BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
• AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
• Designing peptide inhibitors for possible COVID-19 treatments
• Chinese scientists discover the inhibitors of SARS-CoV-2

Learn More Other Chemicals

• Dabrafenib

  1195765-45-7

• BOC-VAL-VAL-OH

  69209-73-0

• BMS 303141

  943962-47-8

• (2S)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanamide Formula

  60117-17-1

• (2S)-2-acetamido-6-amino-N-[(2S)-2-amino-3-methylbutanoyl]-N-propylhexanamide Formula

  57899-96-4

• 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Formula

  26130-02-9

• L-Tyrosyl-L-phenylalanine Structure

  17355-11-2

• C-REACTIVE PROTEIN FRAGMENT 77-82 Structure

  130349-01-8

• What is Sildenafil

  139755-83-2

• What is Dacomitinib

  1110813-31-4